SJIM
BIB icon

St. Johns Investment Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

St. Johns Investment Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-765
Closed -$53K – 161
2018
Q3 		$53K Buy
+765
New +$50K 0.04% 98
2017
Q4 		– Sell
-905
Closed -$55K – 162
2017
Q3 		$55K Buy
+905
New +$51.5K 0.04% 106

Other funds holding BIB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

St. Johns Investment Management's BIB Position: Q4 2018 in Review

St. Johns Investment Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2018, closing a stake of 765 shares — an estimated $53K sold.

St. Johns Investment Management first reported a position in BIB in Q3 2017 and held it in 2 quarters. The position peaked at $55K in Q3 2017. 27 funds tracked by Wall St. Rank hold BIB as of Q4 2018.

  • St. Johns Investment Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2018 after selling out during the quarter.
  • St. Johns Investment Management sold 765 ProShares Ultra NASDAQ Biotechnology shares in Q4 2018, an estimated $53K.
  • St. Johns Investment Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2017 and held it in 2 quarters.
  • St. Johns Investment Management's ProShares Ultra NASDAQ Biotechnology position peaked at $55K in Q3 2017.
  • 27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2018.

Based on St. Johns Investment Management's 13F filing for Q4 2018, filed 5 Feb 2019.